Hi Lopez, you know my views with regards stem cell therapies from my previous postings. In this specific case (Pediatric GVHD), I believe that the data from the trials, the quantitative analysis of of the potency- survival rate relationship (product quality/strength that the company has addressed) and the results of a multitude of studies (in vivo and in vitro) conducted around the world leaves me with little doubt that Remestemcel-L has demonstrated that it is the only ethical and moral treatment available at the moment. When you consider the history and results from Ruxolitinib, Remestemcel-L is a far better alternative with demonstrated superior benefits, specially in those with the most severe cases. Fingers crossed
FDA ODAC Meeting Material discussion analysis, page-383
-
- There are more pages in this discussion • 109 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |